Skip to main content
Premium Trial:

Request an Annual Quote

Artemis to Provide Aventis with Genetically Engineered Mice

NEW YORK, Feb. 9 (GenomeWeb News) - Artemis Pharmaceuticals said today that it has signed a deal to use its ArteMice platform to generate genetically engineered mice for French drug maker Aventis.


According to Artemis, Aventis will use the mice in drug research for gene function analysis, as well as for testing novel drug candidates. Artemis said it will also provide Aventis with licenses to certain Cre transgenic mice, including the CreER-gene switch mouse, for use in in vivo gene function studies.


Financial terms of the arrangement were not disclosed.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.